Illumina earnings jump start 2026 rally

Illumina (ILMN) recently reported quarterly revenue of $1.09b, up 4.8% year on year and 1.8% above analyst expectations. The stock has climbed 54.2% since the announcement to $195.42.

Illumina’s recent earnings beat, coupled with news of fresh competition from Roche’s Axelios NGS system and updated broker views, has coincided with strong momentum, with a 30-day share price return of 18.14% and a 1-year total shareholder return of 93.17% despite a weaker 5-year total shareholder return.

If Illumina’s rebound has your attention, this could be a good moment to see what else is moving in healthcare genomics and AI, starting with 40 healthcare AI stocks.

After a 54% post earnings surge, Illumina now trades above the average analyst target yet still screens at a discount to some intrinsic estimates. Is the market being too cautious, or already pricing in a full rebound?

Most Popular Narrative: 30% Overvalued

At a last close of $191.76 versus a narrative fair value of $147.17, Illumina is framed as ahead of its underlying cash flow story, with that gap built on specific growth and margin assumptions rather than pure sentiment.

Operational efficiencies, disciplined cost controls, and targeted share repurchases have already resulted in notable operating margin and EPS improvements, and further scaling, along with tax headwinds turning into tailwinds, sets the stage for continued net margin and earnings growth over the next several years.

Want to see what sits behind that confidence in Illumina? The narrative leans on steady revenue growth, firmer margins, and a future earnings multiple that has to do some heavy lifting. Curious which specific profit and cash flow paths are being penciled in to justify that $147.17 fair value tag?

Result: Fair Value of $147.17 (OVERVALUED)

However, Illumina’s story can change quickly if research funding remains tight or if China related restrictions continue to pressure instrument and consumables demand.

Another View on Illumina’s Value

The most popular Illumina narrative argues the stock is ahead of its cash flow story, yet our DCF model points the other way, with a fair value estimate of $257.19 versus the current $191.76, implying it screens as undervalued on that framework. Which lens do you trust more when the signals conflict?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Illumina for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Illumina drawing strong opinions on both sides, this is a good time to act quickly and review the full picture for yourself, including the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Illumina?

If Illumina has sharpened your focus, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.

• Target resilient income by scanning for 9 dividend fortresses that can help anchor your portfolio when growth stories take a breather.
• Hunt for potential bargains with the 45 high quality undervalued stocks and see which stocks stand out on quality and pricing.
• Prioritize sleep at night holdings by checking the 74 resilient stocks with low risk scores that score well on financial strength and stability metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.